Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET
Company Participants
Ali Grande - Chief Financial Officer
Patrick McEnany - Chairman and Chief Executive Officer
Jeffrey Del Carmen - Chief Commercial Officer
Steven Miller - Chief Operating Officer and Chief Scientific Officer
Conference Call Participants
Les Sulewski - Truist
Scott Henry - ROTH Capital
Operator
Good day, ladies and gentlemen and welcome to the Catalyst Pharmaceuticals Incorporated Third Quarter 2022 Financial Results Conference Call. All lines have been placed on a listen-only mode, and the floor will be open for questions and comments following the presentation. [Operator Instructions]
At this time, it is my pleasure to turn the floor over to your host, Ali Grande, Chief Financial Officer. Ma’am, the floor is yours.
Ali Grande
Good morning, everyone and thank you for joining our conference call to discuss Catalyst’s third quarter 2022 financial results and corporate highlights. Leading the call today is Patrick McEnany, Chairman and Chief Executive Officer. We’re also joined by Dr. Steven Miller, our Chief Operating Officer and Chief Scientific Officer and Jeffrey Del Carmen, our Chief Commercial Officer. Further for the Q&A session, we will also have Dr. Gary Ingenito, our Chief Medical and Regulatory Officer.
Before we begin, I would like to remind you that in the following comments and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates and projections, and are not guarantees of future performance. They involve risks, uncertainties and assumptions that are difficult to predict and may prove not to be accurate, especially in light of the continued effects of COVID-19. Actual results may vary from the expectations contain in our forward-looking statements. The forward-looking statements should be considered only in conjunction with a detailed information contained in our SEC filings, including the risk factors described in our 2021 annual report on Form 10-K.
At this time, I will turn over the call to Pat.
Patrick McEnany
Thanks, Ali. Good morning, everyone and thank you for joining us today on our third quarter 2022 financial results and corporate update call. We are incredibly proud to report our outstanding third quarter financial results, which marks another consecutive quarter of Firdapse’ revenue growth and an all-time high recorded quarterly net product revenue of $57.2 million, representing a 59.3% increase over the third quarter of 2021.